Skip to main content

ACS & ASCO are Stronger Together: Cancer.Net content is now available on cancer.org.

 

Survival Rates for Uterine Sarcoma

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They can’t tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they can’t predict what will happen in any particular person’s case. These statistics can be confusing and may lead you to have more questions. Ask your doctor how these numbers might apply to you.

What is a 5-year relative survival rate?

A relative survival rate compares people with the same type and stage of uterine sarcoma to people in the overall population. For example, if the 5-year relative survival rate for a specific stage of uterine sarcoma is 90%, it means that people who have that cancer are, on average, about 90% as likely as people who don’t have that cancer to live for at least 5 years after being diagnosed.

Where do these numbers come from?

The American Cancer Society relies on information from the Surveillance, Epidemiology, and End Results (SEER) database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for uterine sarcoma in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by FIGO or AJCC TNM stages (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

  • Localized: There is no sign the cancer has spread outside of the uterus.
  • Regional: The cancer has spread outside the uterus to nearby structures or lymph nodes.
  • Distant: The cancer has spread to distant parts of the body such as the lungs, liver, or bones.

5-year relative survival rates for uterine sarcoma

These numbers are based on women diagnosed with uterine sarcoma between 2012 and 2018. These survival rates differ based on type of uterine sarcoma (leiomyosarcoma, undifferentiated sarcoma, endometrial stromal sarcoma - low grade).

Leiomyosarcoma

SEER* Stage

5-Year Relative Survival Rate

Localized

60%

Regional

37%

Distant

12%

All SEER stages combined 38%

Undifferentiated sarcoma

SEER* Stage

5-Year Relative Survival Rate

Localized

71%

Regional

37%

Distant

18%

All SEER stages combined 43%

Endometrial stromal sarcoma - low grade*

SEER* Stage

5-Year Relative Survival Rate

Localized

>99.5%

Regional

94%

Distant

80%

All SEER stages combined 96%

*The outlook for high-grade endometrial stromal sarcoma tends to be much worse than for low-grade endometrial stromal sarcoma, and is more likely to be similar to that for undifferentiated sarcoma (see table above).

*SEER=Surveillance, Epidemiology, and End Results

Understanding the numbers

  • These numbers apply only to the stage of the cancer when it is first diagnosed. They do not apply later on if the cancer grows, spreads, or comes back after treatment.
  • These numbers don’t take everything into account. Survival rates are grouped based on how far the cancer has spread, but your age, overall health, tumor grade, tumor type, how well the cancer responds to treatment, and other factors can also affect your outlook.
  • People being diagnosed with uterine sarcoma now may have a better outlook than these numbers show. Treatments improve over time, and these numbers are based on people who were diagnosed and treated at least five years earlier.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

Gaillard S and Secord AA. Staging, treatment, and prognosis of endometrial stromal sarcoma and related tumors and uterine adenosarcoma. In: Chakrabarti A and Vora SR, eds. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Accessed June 7, 2022.

Hensley ML and Leitao MM. Treatment and prognosis of uterine leiomyosarcoma. In: Chakrabarti A and Vora SR, eds. UpToDate. Waltham, Mass.: UpToDate, 2021. https://www.uptodate.com. Accessed June 7, 2022.

SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. Accessed at https://seer.cancer.gov/explorer/ on February 23, 2023.

Last Revised: March 1, 2023

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.